BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Interviews » Page 11

BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.

Inside Scoop on Biostage, a World Leader in Bioengineered Organs

October 30, 2017 By Cade Hildreth (CEO) Leave a Comment

BioStage - Bioengineered Organs

BiostageBiostage is a clinical-stage company specializing in bioengineered organ implants to treat cancer and other conditions involving the esophagus, bronchus and trachea. In August 2017, Biostage transplanted its esophageal implant product into its first patient worldwide, a 75-year old man with cancer. On the heels of this historic accomplishment, I am pleased to share this interview with Jim McGorry, President and CEO at Biostage, Inc. In this interview, we discuss the company’s vision, its research partnerships, clinical trial strategy, and five-year goals.

Please note that this interview was conducted prior to Biostage’s breach and failure to fund by First Pecos.

Read on to learn more about how Biostage is introducing bioengineered organ implants to the regenerative medicine landscape. [Read more…]

Filed Under: Cell Therapy, Interviews Tagged With: Biostage

Will Glycostem Release 1st Allogeneic NK Cell Product with Off-the-Shelf Potential?

October 3, 2017 By Cade Hildreth (CEO) Leave a Comment

Glycostem Allogeneic NK Cells
Troels Jordansen, Chairman and CEO of Glycostem
Troels Jordansen, Glycostem Chairman & CEO

This interview comes shortly after Novartis became the first company to get a gene therapy approved in the United States, the CAR-T cell therapy, Kymriah®. The historic event demonstrates to investors, the public and funding providers alike that cell therapy is a sector that has emerged, no longer one that is evolving in the future. There are close to 40 companies developing redirected T cells or NK cells for therapeutic use. There are also 800+ cell therapy clinical trials underway around the world, and a considerable amount of research and preclinical work taking place across the cell therapy sector.

In the light of the recent Gilead takeover of Kite Pharma for $11 billion, the cellular immunotherapy sector is in focus among both investors and oncology and non-oncology companies. The search for the “next Kite” has begun!

Glycostem is a 10-year old clinical stage cellular immunotherapy company based in The Netherlands. The uniqueness around Glycostem, beyond that it is a privately funded company with strong phase I safety clinical trial data, is that it may become the first company with an allogeneic off-the- shelf product (oNKord®). This would potentially position NK cell technology to leapfrog CAR-T cell products, due to a safer profile, lower production costs, off-the- shelf status and positive clinical trial data. [Read more…]

Filed Under: CAR-T, Interviews, Stem Cell News Tagged With: Glycostem, interview, NK cells

Genetically Modified Muscle Progenitor Cells with Stem Cell Medicine Ltd.

October 2, 2017 By Cade Hildreth (CEO) 1 Comment

Stem Cell Medicine – A Model for Advancing Cellular Therapies in Combination with Pharmaceutical Products

In the world of stem cells, there are a number of well-recognized market participants that receive a great deal of attention from the stem cell community.

At the same time, there are brilliant companies that quietly operate under the radar screen, building themselves up one intelligent and methodical step at a time. [Read more…]

Filed Under: Interviews, MSCs, Neural Stem Cells, Stem Cells Tagged With: interview, neural stem cells, stem cell medicine

Cord Blood Transplantation with Dr. Milano of Fred Hutchinson

August 18, 2017 By Cade Hildreth (CEO) Leave a Comment

Dr. Milano Speaks on Trends in Cord Blood Transplantation (CBT) - Interview by Cord Blood World Europe

Cord Blood Transplantation - Fred Hutch

I had the honor of interviewing Dr. Filippo Milano, Associate Director of Cord Blood Transplantation at the Fred Hutchinson Cancer Research Centre about cord blood transplantation. In this interview, Dr. Milano speaks about trends in cord blood transplantation (CBT) that are affecting the global cord blood industry. [Read more…]

Filed Under: Cord Blood, Interviews Tagged With: cord blood

Growing Stem Cells in Suspension Bioreactors with Dr. Angel of Accellta

July 30, 2017 By Cade Hildreth (CEO) Leave a Comment

Exclusive Q&A Interview with Dr. Itzchak Angel, CEO of Israeli Stem Cell Company, Accellta

Accellta IsraelDr. Itzchak Angel, CEO of the Israeli stem cell company, Accellta, has more than 30 years of experience guiding the business development efforts of new and established companies across the Israeli pharmaceutical industry. Dr. Angel was formerly Vice President of R&D at Proteologics Ltd. and at D-Pharm Biopharmaceuticals. Before those positions, he served as the head of pharmacology in Synthelabo (now Sanofi) where he launched blockbuster drugs such as Xatral, Ambien and Mizollen into the marketplace. [Read more…]

Filed Under: HSCs, Interviews, iPS Cells, MSCs, Stem Cells Tagged With: Accellta, interview, stem cells

  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 15
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97

Featured Posts

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.